Capricor Therapeutics (NASDAQ:CAPR) Releases Earnings Results, Beats Expectations By $0.27 EPS

Share on StockTwits

Capricor Therapeutics (NASDAQ:CAPR) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.27, Fidelity Earnings reports. The company had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.22 million. Capricor Therapeutics had a negative return on equity of 270.78% and a negative net margin of 794.63%.

Shares of NASDAQ:CAPR traded down $0.31 during midday trading on Friday, reaching $2.20. The company had a trading volume of 121,100 shares, compared to its average volume of 285,875. Capricor Therapeutics has a 1-year low of $2.01 and a 1-year high of $10.70. The business’s 50 day moving average price is $2.81 and its 200 day moving average price is $2.63. The stock has a market cap of $9.71 million, a PE ratio of -0.42 and a beta of 1.79.

A number of brokerages have recently commented on CAPR. Maxim Group restated a “hold” rating on shares of Capricor Therapeutics in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $19.50 price target on shares of Capricor Therapeutics in a report on Friday, October 11th. Zacks Investment Research upgraded Capricor Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a report on Thursday, October 31st. Finally, ValuEngine raised Capricor Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured Article: Convertible Shares

Earnings History for Capricor Therapeutics (NASDAQ:CAPR)

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.